公开(公告)号：US12097197B2

公开(公告)日：2024-09-24

申请号：US18069204

申请日：2022-12-20

申请人： Slayback Pharma LLC

发明人： Ashish Anilrao Dubewar ,  Rahul Dhulaji Bhise ,  Mahadeo Vasant Mahadik ,  Shanker Mamidi ,  Mayur Anshiram Adhav ,  Raghavender Rao Kategher ,  Nagaraj Gangam ,  Sumitra Ashokkumar Pillai ,  Praveen Kumar Subbappa

IPC分类号： A61K31/497 ,  A61K9/00 ,  A61K31/473

CPC分类号： A61K31/497 ,  A61K9/0019 ,  A61K31/473

摘要： The present invention relates to stable liquid compositions suitable for parenteral administration in the form of a solution comprising:



(a) netupitant and optionally palonosetron;
(b) at least one pharmaceutically acceptable stabilizer;
(c) at least one pharmaceutically acceptable solubilizer; and
(d) at least one pharmaceutically acceptable vehicle,
wherein netupitant is present at a concentration of about 0.5 mg/mL to about 20 mg/mL and the solution has a pH of about 2 to about 6.




The compositions are suitable for subcutaneous, intravenous, or intramuscular administration. The invention further relates to methods for manufacturing the compositions and methods of using such compositions for prevention, treatment or management of nausea and vomiting.

公开(公告)号：US20240197705A1

公开(公告)日：2024-06-20

申请号：US18420099

申请日：2024-01-23

申请人： Slayback Pharma LLC

发明人： Shailendra Mandge ,  Venkateshwar Reddy Keesara ,  Harish Gunda ,  Naga Venkata Durga Prasad Ketha ,  Satheesh Balasubramanian ,  Sumitra Ashokkumar Pillai ,  Sushant Omprakash Dube ,  Praveen Kumar Subbappa

IPC分类号： A61K31/444 ,  A61K9/48

CPC分类号： A61K31/444 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4891

摘要： The present invention relates to stable pharmaceutical compositions comprising apixaban or its pharmaceutically acceptable salts thereof. The present invention further relates to a capsule composition comprising a therapeutically effective amount of apixaban solubilized or dispersed in a pharmaceutically acceptable carrier, wherein the therapeutically effective amount of apixaban ranges from about 0.5 mg/unit dosage form to about 50 mg/unit dosage form. The present invention also provides manufacturing processes thereof and use of the said compositions for prevention, treatment or prophylaxis of disorders in human patients in need thereof.

公开(公告)号：US20240189222A1

公开(公告)日：2024-06-13

申请号：US18444310

申请日：2024-02-16

申请人： SLAYBACK PHARMA LLC

发明人： Rahul Dhulaji BHISE ,  Ajay Kumar SINGH ,  Mahadeo Vasant MAHADIK ,  Ashish Anilrao DUBEWAR ,  Molugu Prashanth REDDY

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K31/27 ,  A61K31/40 ,  A61K47/18

CPC分类号： A61K9/0019 ,  A61K9/08 ,  A61K31/27 ,  A61K31/40 ,  A61K47/183

摘要： Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

公开(公告)号：US11931370B2

公开(公告)日：2024-03-19

申请号：US17961943

申请日：2022-10-07

申请人： Slayback Pharma LLC

发明人： Shailendra Mandge ,  Harish Gunda ,  Naga Venkata Durga Prasad Ketha ,  Venkateshwar Reddy Keesara ,  Satheesh Balasubramanian ,  Sumitra Ashokkumar Pillai

IPC分类号： A01N43/00 ,  A01N43/46 ,  A61K9/00 ,  A61K9/08 ,  A61K31/55 ,  A61K31/675 ,  A61K47/10 ,  A61K47/14

CPC分类号： A61K31/675 ,  A61K9/0053 ,  A61K9/08 ,  A61K47/10 ,  A61K47/14

摘要： The present invention relates to stable liquid oral compositions of cyclophosphamide having extended stability, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cyclophosphamide. The invention also relates to a kit comprising stable liquid oral compositions of cyclophosphamide.

公开(公告)号：US11872305B2

公开(公告)日：2024-01-16

申请号：US17822756

申请日：2022-08-26

申请人： Slayback Pharma LLC

发明人： Ashish Anilrao Dubewar ,  Amit Anil Charkha ,  Sumitra Ashokkumar Pillai ,  Pradeep Kumar Kare ,  Kumar Swamy Ummiti ,  Shanker Mamidi ,  Mayur Anshiram Adhav

IPC分类号： A01N37/00 ,  A61K31/215 ,  A01N37/12 ,  A01N37/44 ,  A61K31/24 ,  A01N25/00 ,  A61K9/00 ,  A61K47/18 ,  A61K47/10 ,  A61K31/225 ,  A61K31/221 ,  A61K47/12

CPC分类号： A61K9/0019 ,  A61K31/221 ,  A61K31/225 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183

摘要： The present invention relates to injectable pharmaceutical compositions comprising therapeutically effective amount of succinylcholine chloride, one or more pharmaceutically acceptable aqueous solvents, and one or more stabilizing agents selected from aliphatic polyols; lower alkyl alcohols; amino acids having at least one additional amino, carboxyl or hydroxyl group; amino alcohols; and aliphatic dicarboxylic acids having at least one hydroxyl or amino group, or α-β unsaturation. The compositions are stable at room temperature for at least 30 days. Methods of manufacturing the injectable pharmaceutical compositions are also provided. The composition may be provided in a sealed container, e.g., an ampoule, vial and pre-filled syringe, and are suitable for subcutaneous, intravenous or intramuscular administration as an adjunct to general anesthesia, to facilitate tracheal intubation, and/or to provide skeletal muscle relaxation during surgery or mechanical ventilation.

公开(公告)号：US11766438B2

公开(公告)日：2023-09-26

申请号：US17239007

申请日：2021-04-23

申请人： Slayback Pharma LLC

发明人： Sushant Omprakash Dube ,  Purushottam Dattatraya Kulkarni ,  Purushottam Sakhahari Pattewar ,  Sumitra Ashokkumar Pillai

IPC分类号： A61K31/277 ,  A61K31/519 ,  A61K9/00 ,  A61K47/12 ,  A61K47/40 ,  A61K47/14 ,  A61K47/26 ,  A61K47/20 ,  A61K9/08

CPC分类号： A61K31/519 ,  A61K9/0053 ,  A61K9/08 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/26 ,  A61K47/40

摘要： The present invention relates to liquid pharmaceutical compositions of tofacitinib or its pharmaceutically acceptable salts thereof, suitable for oral administration, that are stable under varying storage conditions for extended periods of time. The present invention also relates to methods of treating auto-immune disorders using the stable liquid pharmaceutical compositions of tofacitinib. A stable liquid pharmaceutical composition of tofacitinib according to the invention comprises of (a) tofacitinib at a concentration of about 1 mg/mL or more; (b) a pharmaceutically acceptable liquid vehicle; (c) at least one anti-oxidant; and (d) optionally one or more other pharmaceutically acceptable excipients.

公开(公告)号：US20230285368A1

公开(公告)日：2023-09-14

申请号：US18117808

申请日：2023-03-06

申请人： Slayback Pharma LLC

发明人： Sushant Omprakash Dube ,  Girish G. Kore ,  Naga Venkata Durga Prasad Ketha ,  Sumitra Ashokkumar Pillai ,  Praveen Kumar Subbappa

IPC分类号： A61K31/437 ,  A61K47/26 ,  A61K47/10 ,  A61K47/20 ,  A61K47/32

CPC分类号： A61K31/437 ,  A61K47/26 ,  A61K47/10 ,  A61K47/20 ,  A61K47/32

摘要： Liquid pharmaceutical compositions of apixaban or pharmaceutically acceptable salts thereof are described. More specifically, stable oral liquid pharmaceutical compositions of apixaban for oral administration are provided, wherein the composition is stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of apixaban at concentrations of 0.4 mg/mL or more are provided. Stable oral liquid compositions of apixaban, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by apixaban are disclosed.

公开(公告)号：US20230285341A1

公开(公告)日：2023-09-14

申请号：US18130597

申请日：2023-04-04

申请人： SLAYBACK PHARMA LLC

发明人： Sushant Omprakash Dube ,  Purushottam Sakhahari Pattewar ,  Pankaj Kisan Chatki ,  Sumitra Ashokkumar Pillai

IPC分类号： A61K31/197 ,  A61K9/00 ,  A61K9/10

CPC分类号： A61K31/197 ,  A61K9/0053 ,  A61K9/10

摘要： The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.

公开(公告)号：US20230270736A1

公开(公告)日：2023-08-31

申请号：US18312857

申请日：2023-05-05

申请人： SLAYBACK PHARMA LLC

发明人： Sushant Omprakash DUBE ,  Suprit Dilip SAOJI ,  Pankaj Kisan CHATKI ,  Sumitra Ashokkumar PILLAI ,  Girish G. KORE

IPC分类号： A61K31/47 ,  A61K9/10

CPC分类号： A61K31/47 ,  A61K9/10

摘要： Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.

公开(公告)号：US11707450B1

公开(公告)日：2023-07-25

申请号：US17877476

申请日：2022-07-29

申请人： SLAYBACK PHARMA LLC

发明人： Harish Govindaraja Setty Chinnari ,  Somashekhar Battini ,  Sumitra Ashokkumar Pillai ,  Lourdu Chinnu Thippabattuni ,  Satheesh Balasubramanian

IPC分类号： A61K31/4184 ,  A61K9/00 ,  A61K47/02 ,  A61K47/10 ,  A61K9/08

CPC分类号： A61K31/4184 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/02 ,  A61K47/10

摘要： Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine or its pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.